



PHARMA MONTHLY

DECEMBER 2025

PROGRESSIVE®
Your Progress Our Priority...

Key News for the Month

Company

- USFDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich
- Sun Pharma launches Ilumya for psoriasis treatment in India
- Lupin gets USFDA nod for biosimilar drug
- Lupin Pharma, TPG Capital & EQT in talks to acquire Lalvani family-owned Vitabiotics
- Sun Pharma unit to invest Rs3,000cr on new plant in Madhya Pradesh
- Novo Nordisk gears up for December Ozempic launch in India: Sources
- Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment
- Zydus receives EIR for the injectable facility located at Jarod
- USFDA issues Form 483 with 3 observations to Ipc'a Tarapur plant
- Lupin gets USFDA nod for multiple sclerosis drug
- Biocon to make Biocon Biologics a wholly owned subsidiary
- Abbott asks stockists to buy only from authorised suppliers
- Venus Remedies marks completion of AMR licensing milestones with final Rs11cr payment
- Dr. Reddy's inks licensing deal to sell Immutep's cancer drug
- Zydus and Formycon enter into an exclusive partnership for the licensing and supply of biosimilar to Keytruda in the US and Canadian markets
- Zydus launches biosimilar Denosumab 120mg SC; protecting bone health in cancer patients
- Cipla has launched Yurpeak for the treatment of obesity and type 2 diabetes
- Delhi HC allows Sun Pharma to manufacture, export its own weight loss drug
- Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection, 350mg/vial Single-Dose Vial
- Alembic Pharmaceuticals receives USFDA final approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%
- Suven Life Sciences achieved 100% patient enrolment milestone in Phase-2b clinical trial of Ropanicant
- Unit V of Aurobindo's WoS was inspected and ended with Form 483, 3 observations
- USFDA issues Form 483 to Dr. Reddy's Andhra Pradesh formulations unit
- Lupin Manufacturing Solutions and PolyPeptide announce a strategic alliance to scale global peptide supply chain

Industry

- Cough syrup row puts regulators on overdrive to test pharma products
- Respiratory drug sales peak in November amid worsening AQI
- Slimmer price tag helps Wegovy sales gain weight
- India's pharma exports cross USD30bn: Commerce Secretary, Rajesh Agrawal

Global

- USFDA launches fresh safety scrutiny of approved RSV therapies for infants
- Novo gets FDA warning letter at troubled Indiana site formerly owned by Catalent
- GSK rounds out year of approvals with FDA asthma nod for long-acting biologic Exdensur
- Novo Nordisk cuts price of weight-loss drug Wegovy in China

Tentative ANDA Approvals

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
Lupin	Siponimod Tablets	0.25/1/2mg	Indicated for the treatment of relapsing forms of multiple sclerosis (MS)	Mayzent (Novartis Pharmaceuticals Corporation)	USD195mn (annual sales Sept'25)
Granules India	Amphetamine ER Orally Disintegrating	3.1/6.3/9.4/12.5/15.7/18.8mg	Indicated for the treatment of Attention Deficit Hyperactivity Disorder	ADZENYS XR-ODT (Aytu BioPharma)	USD172mn

Source: Media Reports and Company Press Releases

Final ANDA Approvals

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
Lupin	Armlupeg	6mg/0.6mL injection	Indicated to decrease the incidence of infection, as manifested by febrile neutropenia	Neulasta (Amgen, Inc.)	USD1295mn (annual sales Sept'25)
Caplin Point	Acetaminophen Injection	1000mg/100mL (10mg/mL) Single-dose Infusion Bags	Indicated for the management of mild to moderate pain in adult and pediatric patients	Acetaminophen Injection (Mallinckrodt Pharmaceuticals Ireland Ltd)	USD86mn (annual sales Oct'25)
Caplin Point	Linezolid Injection	600mg/300mL (2mg/mL) Single-dose Infusion Bags	Indicated to treat serious bacterial infections	ZYVOX (Pfizer Inc.)	USD23mn (annual sales Oct'25)
Alembic Pharma	Loteprednol Etabonate and Tobramycin Ophthalmic Suspension	0.5%/0.3%	Indicated for steroid-responsive inflammatory ocular conditions	Zylet (Bausch & Lomb Inc.)	-
Alembic Pharma	Travoprost Ophthalmic Solution	0.004%	Indicated for the reduction of elevated intraocular pressure (IOP) in patients	Travatan Z (Sandoz Inc.)	USD61mn

Source: Media Reports and Company Press Releases

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
3B BlackBio Dx Ltd	1405	11.6%	-3.4%	-29.0%
Aarti Drugs Ltd	412	-1.0%	-10.2%	-10.6%
Aarti Pharmalabs Ltd	752	7.1%	-15.7%	9.5%
Abbott India Ltd	29070	-2.5%	-18.4%	-2.3%
Acutaas Chemicals Ltd	1703	-3.9%	48.8%	-20.7%
Advanced Enzyme Technologies Ltd	301	-3.7%	-6.3%	-13.6%
Ajanta Pharma Ltd	2770	8.2%	7.6%	-5.5%
Akums Drugs and Pharmaceutical Ltd	454	7.0%	-22.4%	-28.9%
Alembic Pharmaceuticals Ltd	848	-6.6%	-18.6%	-20.3%
Alivus Lifesciences Ltd	917	1.4%	-8.5%	-6.7%
Alkem Laboratories Ltd	5505	-1.8%	11.5%	-2.3%
Anuh Pharma Ltd	80	0.5%	-62.6%	-64.4%
Apollo Hospitals Enterprise Ltd	7043	-3.4%	-2.8%	-3.4%
Artemis Medicare Services Ltd	271	-2.9%	6.5%	-14.1%
Aster DM Healthcare Ltd	616	-7.9%	3.4%	20.0%
AstraZeneca Pharma India	9010	-0.5%	1.6%	23.3%
Aurobindo Pharma Ltd	1181	-2.8%	4.1%	-11.5%
Bajaj Healthcare Ltd	415	-3.4%	-17.7%	-27.7%
Biocon Ltd	394	-0.15%	10.8%	7.8%
Bliss GVS Pharma Ltd	164	4.9%	3.4%	-0.7%
Blue Jet Healthcare Ltd	530	-6.7%	-39.7%	-6.1%
Caplin Point Laboratories Ltd	1841	-3.5%	-13.0%	-26.4%
Cipla Ltd	1511	-0.8%	0.4%	-1.2%
Cohance Lifesciences Ltd	529	-4.5%	-45.3%	-53.5%
Concord Biotech Ltd	1345	-6.0%	-27.2%	-39.1%
Dishman Carbogen Amics Ltd	248	4.2%	-1.5%	-8.3%
Divi's Laboratories Ltd	6395	-0.4%	-6.1%	4.8%
Dr. Agarwal's Health Care Ltd	509	-4.6%	25.7%	-
Dr. Lal PathLabs Ltd	1482	-51.5%	-47.0%	-50.6%
Dr. Agarwals Eye Hospital Ltd	5334	-7.4%	18.0%	-13.2%

Source: BSE website; All prices are as on 31st December, 2025

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
Dr. Reddy's Laboratories Ltd	1271	0.9%	-1.0%	-8.4%
Emcure Pharmaceuticals Ltd	1364	-4.7%	5.3%	-5.6%
Eris Lifesciences Ltd	1504	-4.8%	-10.7%	9.4%
FDC Ltd	423	3.6%	-13.2%	-15.1%
Fermenta Biotech Ltd	348	25.2%	3.6%	-4.4%
Fischer Medical Ventures Ltd	42	-13.4%	-95.3%	-94.0%
Fortis Healthcare Ltd	884	-2.4%	11.2%	22.8%
Gland Pharma Ltd	1722	-0.2%	-6.0%	-3.2%
GSK Pharmaceuticals Ltd	2471	-1.0%	-27.0%	9.7%
Glenmark Pharmaceuticals Ltd	2036	4.9%	16.1%	26.5%
Global Health Ltd	1186	-4.7%	4.1%	9.9%
GPT Healthcare Ltd	140	0.4%	-3.3%	-23.6%
Granules India Ltd	599	5.2%	20.9%	1.2%
Gufic Biosciences Ltd	337	-4.2%	-7.4%	-26.1%
Gujarat Themis Biosyn Ltd	442	8.4%	27.3%	44.9%
HealthCare Global Enterprises Ltd	662	-10.1%	19.6%	35.3%
Hester Biosciences Ltd	1592	-3.4%	-13.9%	-33.5%
Hikal Ltd	227	0.5%	-36.9%	-41.8%
Indegene Ltd	521	-1.1%	-9.4%	-13.8%
Indoco Remedies Ltd	235	-9.3%	-25.7%	-29.9%
Indraprastha Medical Corp. Ltd	448	-11.1%	-7.9%	-14.4%
Innova Captab Ltd	717	-0.04%	-16.5%	-35.9%
IOL Chemicals and Pharma Ltd	82	-8.4%	-15.6%	-79.8%
IPCA Laboratories Ltd	1424	0.2%	2.6%	-15.9%
J.B.Chemicals & Pharmaceuticals Ltd	1820	2.9%	8.4%	-1.3%
Jagsonpal Pharmaceuticals Ltd	193	-11.6%	-13.7%	-68.4%
Jubilant Pharmova Sciences Ltd	1075	-2.9%	-11.1%	-2.7%
Jupiter Life Line Hospitals Ltd	1391	-5.5%	-7.0%	-10.8%
KMC Speciality Hospitals Ltd	76	-3.2%	19.4%	0.3%
Kopran Ltd	150	6.5%	-20.5%	-29.4%

Source: BSE website; All prices are as on 31st December, 2025

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
Kovai Medical Center & Hospital Ltd	5751	-3.0%	-1.6%	-3.6%
KIMS Ltd	607	-12.0%	-9.9%	1.3%
Krsnaa Diagnostics Ltd	720	-11.6%	2.1%	-18.5%
Kwality Pharmaceuticals Ltd	1108	20.0%	4.5%	27.9%
Laurus Labs Ltd	1108	7.7%	52.9%	84.0%
Laxmi Dental Ltd	272	0.02%	-37.5%	-
Lincoln Pharmaceuticals Ltd	483	-4.8%	-14.6%	-38.6%
Lupin Ltd	2112	1.2%	9.0%	-10.2%
Mankind Pharma Ltd	2196	-1.5%	-5.4%	-23.7%
Marksans Pharma Ltd	180	-7.6%	-31.1%	-39.3%
Max Healthcare Institute Ltd	1045	-7.1%	-18.1%	-7.4%
Metropolis Healthcare Ltd	1929	-1.4%	12.9%	-7.0%
Morepen Laboratories Ltd	41	-5.4%	-33.5%	-47.5%
Narayana Hrudayalaya Ltd	1891	-1.0%	-12.9%	48.5%
Natco Pharma Ltd	904	0.1%	-2.6%	-34.9%
Nectar Lifesciences Ltd	20	11.9%	-12.2%	-50.0%
Neuland Laboratories Ltd	15190	-8.3%	26.5%	10.7%
Novartis India Ltd	779	-3.9%	-25.9%	-15.3%
Onesource Specialty Pharma Ltd	1811	12.3%	-17.5%	-
Orchid Pharma Ltd	759	-10.8%	6.4%	-58.0%
Panacea Biotec Ltd	376	3.7%	-11.7%	-9.9%
Pfizer (India) Ltd	4983	0.3%	-12.3%	-5.6%
Piramal Pharma Ltd	172	-6.8%	-15.3%	-35.2%
Poly Medicure Ltd	1776	-8.0%	-20.0%	-32.0%
Procter & Gamble Health Ltd	5701	-2.0%	-3.0%	8.8%
Rainbow Children's Medicare Ltd	1320	-0.7%	-15.6%	-11.8%
RPG Life Sciences Ltd	2321	4.1%	-6.4%	6.6%
Sai Life Sciences Ltd	907	3.9%	17.3%	-
Sanofi Consumer Healthcare India Ltd	4526	-2.1%	-20.5%	-8.1%
Sanofi India Ltd	4092	-6.2%	-35.8%	-33.2%

Source: BSE website; All prices are as on 31st December, 2025

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
Sastasundar Ventures Ltd	296	-9.9%	-0.5%	-6.4%
Senores Pharmaceuticals Ltd	822	2.1%	41.1%	-
Sequent Scientific Ltd	208	-5.9%	7.9%	18.3%
Shalby Ltd	203	-2.0%	9.6%	-11.5%
Shilpa Medicare Ltd	321	-7.7%	-27.2%	-21.3%
Shree Ganesh Remedies Ltd	463	0.7%	-22.7%	-27.0%
Sigachi Industries Ltd	31	-16.0%	-36.2%	-37.7%
SMS Pharmaceuticals Ltd	310	-1.1%	23.8%	29.3%
Solara Active Pharma Sciences Ltd	563	8.3%	-11.7%	-17.0%
Strides Pharma Science Ltd	902	-0.9%	0.4%	36.8%
SPARC Ltd	134	0.1%	-17.1%	-32.9%
Sun Pharmaceutical Industries Ltd	1720	-4.9%	2.5%	-8.7%
Supriya Lifescience Ltd	750	0.6%	6.1%	1.4%
Suraksha Diagnostic Ltd	268	-8.7%	-17.5%	-
Suven Life Sciences Ltd	167	-3.5%	-31.8%	30.4%
Snycom Formulations (India) Ltd	14	-8.6%	-25.9%	-28.7%
Syngene International Ltd	651	1.0%	1.9%	-24.1%
Tarsons Products Ltd	233	1.5%	-41.1%	-42.3%
Themis Medicare Ltd	101	-4.7%	-22.6%	-61.8%
Thyrocare Technologies Ltd	446	-8.2%	-55.0%	-51.2%
Torrent Pharmaceuticals Ltd	3842	2.8%	12.7%	14.3%
Unichem Laboratories Ltd	441	-4.6%	-25.2%	-40.4%
Vijaya Diagnostic Centre Ltd	1062	6.1%	7.8%	0.5%
Vimta Labs Ltd	606	-0.4%	35.0%	-39.1%
Wanbury Ltd	227	-11.4%	-19.1%	-22.3%
Windlas Biotech Ltd	795	1.0%	-10.7%	-23.7%
Wockhardt Ltd	1446	-1.7%	-15.6%	1.9%
Yatharth Hospital & Trauma Care Services Ltd	682	-4.7%	27.4%	20.3%
Zydus Lifesciences Ltd	915	-2.3%	-7.6%	-5.8%


Source: BSE website; All prices are as on 31st December, 2025

NIFTY PHARMA COMPANIES

Company	Price (Rs)	Mcap (Rs mn)	Change		
			1M	6M	12M
Abbott India Ltd	29070	617714	-2.5%	-18.4%	-2.3%
Alkem Laboratories Ltd	5505	658223	-1.8%	11.5%	-2.3%
Aurobindo Pharma Ltd	1181	686043	-2.8%	4.1%	-11.5%
Ajanta Pharma Ltd	2770	346103	8.2%	7.6%	-5.5%
Biocon Ltd	394	526630	-0.2%	10.8%	7.8%
Cipla Ltd	1511	1220453	-0.8%	0.4%	-1.2%
Divi's Laboratories Ltd	6395	1697579	-0.4%	-6.1%	4.8%
Dr. Reddy's Laboratories Ltd	1271	1060836	0.9%	-1.0%	-8.4%
Gland Pharma Ltd	1722	283760	-0.2%	-6.0%	-3.2%
Glenmark Pharmaceuticals Ltd	2036	574533	4.9%	16.1%	26.5%
Ipca Laboratories Ltd	1424	361287	0.2%	2.6%	-15.9%
J.B. Chemicals & Pharmaceuticals Ltd	1820	285076	2.9%	8.4%	-1.3%
Laurus Labs Ltd	1108	598234	7.7%	52.9%	84.0%
Lupin Ltd	2112	964673	1.2%	9.0%	-10.2%
Piramal Pharma Ltd	172	229029	-6.8%	-15.3%	-35.2%
Mankind Pharma Ltd	2290	945238	-1.5%	-5.4%	-23.7%
Sun Pharmaceutical Industries Ltd	1720	4126256	-4.9%	2.56%	-8.7%
Torrent Pharmaceuticals Ltd	3842	1300206	2.8%	12.7%	14.3%
Wockhardt Ltd	1446	234947	-1.7%	-15.6%	1.9%
Zydus Lifesciences Ltd	915	920352	-2.3%	-7.6%	-5.8%

Source: NSE website, Company Research; All prices are as on 31st December, 2025

Nifty Pharma Index Vs. Nifty Index



Source: NSE website


DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai-400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500

Compliance Officer:

Ms. Mamatha Poojari,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500

Grievance Officer:

Email: grievancecell@progressiveshares.com